GET DAILY SIGNALSCVS Health (CVS) vs UnitedHealth Group (UNH): Turnaround Momentum Against Diversified Recovery
Key Takeaways
- CVS is executing a turnaround, having beaten earnings expectations for five consecutive quarters and raised its 2026 profit guidance after improving medical-cost controls.
- UNH is the larger, more diversified operator and has raised its full-year earnings outlook multiple times in 2026 as its insurance margins recover.
- Both companies face elevated medical costs and tight Medicare Advantage (MA) margins, a shared headwind across the managed-care sector.
- CVS carries greater exposure to retail pharmacy and pharmacy benefit manager (PBM) regulation, while UNH is diversified through its Optum services division.
- Each stock has posted strong year-to-date gains, but their paths reflect different trade-offs between growth and profitability.
Introduction
CVS Health and UnitedHealth Group rank among the largest players in U.S. healthcare, yet they operate with distinctly different models. CVS combines a national retail pharmacy network, the Aetna insurance arm, and the Caremark pharmacy benefit manager. UNH pairs the nation’s largest health insurer with Optum, its expanding healthcare-services business. This comparison matters for investors looking to weigh an integrated retailer-insurer’s recovery against a diversified managed-care leader that is regaining margin ground. Examining their performance, positioning, and risks can clarify which approach fits the current environment best.
CVS Overview and Recent Performance
CVS Health breaks down into three segments: Health Care Benefits (Aetna), Health Services (Caremark PBM), and Pharmacy & Consumer Wellness. After a tough 2024 that included an earnings miss and a CEO change, the company has regained traction. In the latest quarter, adjusted EPS climbed roughly 14% year over year to $2.57, topping estimates, while revenue rose about 6% to near $100 billion. Management lifted full-year 2026 adjusted EPS guidance to a range of $7.30 to $7.50. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Aetna drove much of the improvement, with the medical benefit ratio falling to 84.6% from 87.3% a year earlier, reflecting better cost discipline. Recent developments include an FTC settlement on Caremark’s payment model and a move toward biosimilars. These factors have helped shares approach a 52-week high, though Medicare Advantage margins and pharmacy reimbursement pressures remain key risks.
UNH Overview and Recent Performance
UnitedHealth Group operates UnitedHealthcare, the largest U.S. health insurer, together with Optum, which covers pharmacy services, care delivery, and data and technology. Following a difficult 2025 shaped by higher medical costs and regulatory attention, the company has posted a clearer earnings rebound. Adjusted EPS jumped about 61% year over year to $4.69 in the most recent quarter, beating expectations, while revenue eased slightly to roughly $113 billion. Management raised its 2026 adjusted EPS outlook to at least $20.50. The medical care ratio improved to 88.4% from 89.9% a year earlier. From what I see, the firm has deliberately allowed membership to decline to about 48.3 million as it favors profitable growth, especially in Medicare Advantage. Optum’s services turnaround has added support. A recent note that Berkshire Hathaway exited its stake, along with ongoing commercial-cost pressures, has kept sentiment measured.
Head-to-Head Comparison
On business model, CVS is an integrated healthcare conglomerate whose results depend on Aetna’s turnaround plus managing PBM regulatory changes and a lower-margin retail pharmacy operation. UNH is a managed-care leader diversified into Optum, which provides more balanced revenue streams but also broad exposure to insurance utilization trends. On scale, UNH is larger, with full-year revenue expected near $450 billion compared with CVS guidance of at least $405 billion. Both stocks have outperformed recently, though through different drivers. CVS gains stem from insurance-margin recovery and guidance increases after earlier underperformance, while UNH reflects a return to earnings growth even as membership contracts. On risk, CVS faces greater pharmacy reimbursement and PBM regulatory exposure, whereas UNH contends with commercial medical-cost trends and legal scrutiny. Analyst estimate revisions have trended higher for both, though UNH trades at a richer valuation multiple relative to its peers.
My Experience with Tickeron AI Tools
I have found Tickeron’s Trending AI Robots page useful when comparing names like these. It highlights automated strategies that fit current market conditions, each with its own style, timeframe, and documented performance metrics. Reviewing the selection helps put the relative momentum of CVS and UNH into perspective without replacing deeper fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
UNH's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for UNH turned positive on October 05, 2026. Looking at past instances where UNH's MACD turned positive, the stock continued to rise in 29 of 45 cases over the following month. The odds of a continued upward trend are 64%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 09, 2026. You may want to consider a long position or call options on UNH as a result. In 44 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 53%.
UNH moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for UNH crossed bullishly above the 50-day moving average on October 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 44%.
Following a +4.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where UNH advanced for three days, in 182 of 331 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UNH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 53%.
UNH broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for UNH entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating fairly steady price growth. UNH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.802) is normal, around the industry mean (3.597). P/E Ratio (26.731) is within average values for comparable stocks, (133.056). Projected Growth (PEG Ratio) (1.025) is also within normal values, averaging (0.786). UNH has a moderately high Dividend Yield (0.022) as compared to the industry average of (0.009). P/S Ratio (0.757) is also within normal values, averaging (0.569).
The Tickeron Profit vs. Risk Rating rating for this company is 91 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UNH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of hospital and medical service plans
Industry ManagedHealthCare
Advertisement